Printed from Voxsanity (voxsanity.com.au) — NCT05506410 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lymphoma
Lymphoma Trial, Recruiting
NCT05506410
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 70 years old who have a performance status score of 0–2 (a measure of how much the illness affects daily activity — confirm with trial site)
- People whose doctors estimate they are likely to live for more than 6 months
- People who have been confirmed by a tissue or biopsy test to have mantle cell lymphoma (a type of blood cancer)
- People whose blood counts meet certain minimum levels: a type of infection-fighting white blood cell (neutrophils) at a sufficient level, platelets at a sufficient level, and haemoglobin at a sufficient level — with some exceptions for people whose lymphoma has spread to the bone marrow (confirm with trial site)
- People who have at least one tumour that can be measured on a scan, meeting minimum size requirements depending on whether it is inside or outside the lymph nodes
- People whose liver is functioning within acceptable limits on blood tests
- People whose kidneys are functioning within acceptable limits on blood tests
- People whose heart is functioning normally, with no major other serious illnesses
- People of childbearing age (both men and women) who are willing to use adequate contraception throughout the study, and women of childbearing age who have had a negative pregnancy blood test within 7 days before starting the trial
- People who are willing to take part voluntarily, sign a consent form, and attend follow-up visits
- People who are not currently receiving other treatments for their cancer, including traditional herbal/Chinese medicine with anti-cancer intent, immunotherapy, or biological therapies (other than treatments for bone-related symptoms)
Who may not be able to join:
- People with confirmed nerve or psychiatric conditions, including dementia, seizures, a history of substance misuse they are unable to stop, or other conditions that may increase the risk of side effects affecting the brain or nervous system
- People currently taking part in another clinical trial, or who took part in one within the 4 weeks before joining (unless they received no treatment in that trial)
- People with a systemic autoimmune disease or a condition that weakens the immune system
- People who refuse to have blood samples collected
- People who are known to be allergic to any of the drugs used in this trial
- Women who are pregnant or breastfeeding
- People with major illnesses that could interfere with the study results, or people with active uncontrolled infections
- People with a tumour originating in or spreading to the central nervous system (brain or spinal cord)
- People for whom chemotherapy is medically not suitable
- People who are considered by the trial team to be otherwise unsuitable for the trial
- People who have had a serious active infection requiring intravenous antibiotics or a hospital stay in the 4 weeks before joining (other than fever related to the cancer itself)
- People currently receiving other cancer treatments such as radiotherapy, chemotherapy, hormone therapy, biological therapy, or immunotherapy
- People with certain serious medical conditions, including: uncontrolled diabetes; significant heart failure; a heart attack or related event in the past 6 months; certain heart or major blood vessel procedures (such as stenting or bypass surgery) in the past 6 months; certain serious heart rhythm problems; uncontrolled high blood pressure above specific levels; stomach ulcers considered at risk of perforation; active autoimmune diseases such as lupus or rheumatoid arthritis; or severe lung or breathing conditions such as chronic obstructive pulmonary disease or a history of bronchospasm
- People with a condition called haemophagocytic syndrome, where the immune system severely damages the body's own tissues
- People who test positive for hepatitis B (with abnormal virus levels in the blood), hepatitis C (with active virus in the blood), HIV, cytomegalovirus (CMV), or syphilis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Zhang Mingzhi Zhang, The First Affiliated Hospital of Zhengzhou University
Phone: 13838565629
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Zhengzhou University
Registry
ClinicalTrials.gov
Start date
12 August 2022
Est. completion
30 June 2024
Where this trial is recruiting
🇨🇳 China
Primary endpoints
progression free survival（PFS）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.